Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 104.51B |
| Revenue (ttm) | 45.93B |
| Net Income (ttm) | 9.11B |
| Shares Out | 1.22B |
| EPS (ttm) | 7.39 |
| PE Ratio | 16.46 |
| Forward PE | 10.40 |
| Dividend | 3.92 (4.56%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 128,071 |
| Average Volume | 1,684,647 |
| Open | 86.13 |
| Previous Close | 85.89 |
| Day's Range | 85.52 - 86.14 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.37 |
| RSI | 45.00 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe
Sanofi SA's (NASDAQ: SNY) Paris headquarters received an unannounced visit on Tuesday as tax investigators, accompanied by prosecutors and specialist aides, searched the site amid a widening financial...
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
Bayer AG (OTC: BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian. • BMY shares are climbing. Find out why her...
Sanofi (SNY) Study Reveals Cost Benefits in Digital Health Intervention
Sanofi (SNY) Study Reveals Cost Benefits in Digital Health Intervention
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug
Texas Attorney General Ken Paxton escalated his campaign against major drugmakers this week, filing a new lawsuit accusing Sanofi SA (NASDAQ: SNY) and Bristol-Myers Squibb Co (NYSE: BMY) of conceali...
Sanofi (SNY) and Bristol Myers Squibb (BMY) Face Legal Action Over Plavix Marketing
Sanofi (SNY) and Bristol Myers Squibb (BMY) Face Legal Action Over Plavix Marketing
Texas AG Paxton takes aim at Sanofi, Bristol over Plavix
Bristol Myers, Sanofi sued by Texas over Plavix
Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi , accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for...
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
Burlington, Massachusetts--(Newsfile Corp. - November 18, 2025) - Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of aut...
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
BURLINGTON, Mass.--(BUSINESS WIRE)-- #ADCs--Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammato...
SNY Makes Notable Cross Below Critical Moving Average
In trading on Tuesday, shares of Sanofi (Symbol: SNY) crossed below their 200 day moving average of $50.97, changing hands as low as $50.48 per share. Sanofi shares are currently trading off about 2.4...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
Sanofi (SNY) Gains EMA Endorsement for Diabetes Drug Teizeild
Sanofi (SNY) Gains EMA Endorsement for Diabetes Drug Teizeild
Sanofi (SNY) Facility Faces Regulatory Challenges
Sanofi (SNY) Facility Faces Regulatory Challenges
Sanofi, Lilly among winners of EU drug recommendations this week
Sanofi's type 1 diabetes drug recommended for EU approval
The European Medicines Agency's committee has recommended approval of French drugmaker Sanofi's first-of-its-kind drug that delays onset of the insulin-dependent stage 3 of type 1 diabetes, it said on...
Press Release: Sanofi's Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Sanofi's Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild's ability to delay the onset of stag...
Merck (MRK) and Sanofi Await CDC's Hepatitis B Vaccine Decision
Merck (MRK) and Sanofi Await CDC's Hepatitis B Vaccine Decision
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including wholly-ow...
The Zacks Analyst Blog Accenture, Sanofi and Dell
Zacks spotlights fresh research on Accenture, Sanofi, and Dell Technologies, revealing trends in consulting, pharma, and AI-driven tech growth
Top Research Reports for Accenture, Sanofi & Dell Technologies
Accenture, Sanofi, and Dell Technologies stand out in today's top analyst research picks, each navigating growth and market pressures in distinct ways.
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results
REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results
Regeneron and Sanofi's Dupixent succeeds in late-stage study
Sanofi And Regeneron's Dupixent Meets Primary Goal In Phase 3 Allergic Fungal Rhinosinusitis Study
(RTTNews) - Sanofi SA (SNY) on Friday announced that the pivotal LIBERTY-AFRS-AIMS phase 3 study of Dupixent, co-developed with Regeneron Pharmaceuticals Inc. (REGN), for the treatment of individuals ...